89Zr-cetuximab PET imaging in patients with advanced colorectal cancer

89Zr-cetuximab PET imaging in patients with advanced colorectal cancer

Monoclonal antibodies (mAbs) against the epidermal growth factor receptor (EGFR) are used in the treatment of advanced colorectal cancer (mCRC). Approximately 50% of patients benefit despite patient selection for RAS wild type (wt) tumors. Based on the hypothesis that tumor targeting is required for...

Full description

Bibliographic Details
Main Authors: Menke-van der Houven van Oordt, Catharina Willemien, Gootjes, Elske C., Huisman, Marc C., Vugts, Danielle J., Roth, Chantal, Luik, Anne Marije, Mulder, Emma R., Schuit, Robert C., Boellaard, Ronald, Hoekstra, Otto S., van Dongen, Guus AMS, Verheul, Henk M.W.
Format: Online
Language:English
Published: Impact Journals LLC 2015
Online Access:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4745807/

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4745807/

Similar Items